Want to see IMRN full AI Analyst Report?
Top Page
Immuron
(NASDAQ:IMRN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(72.41% Upside)
Action:Reiterated
Date:09/06/26
Overall score reflects a balance of strengths and risks: improving scale and a debt-free balance sheet are positives, but persistent losses and negative free cash flow remain the main constraint. Technicals are currently strong (price above major moving averages with positive MACD), though the elevated RSI indicates the stock may be overextended. Valuation is penalized by negative earnings (negative P/E) and lack of dividend yield data.
Positive Factors
Commercialization traction
Revenue expansion from $0.15M to $7.55M demonstrates that Immuron has moved beyond an early development profile toward commercial traction. A larger revenue base can support broader distribution, strengthen product awareness, and provide a platform for scaling its gastrointestinal portfolio.
Negative Factors
Persistent operating losses
The sizable net and operating losses show that current revenue and gross profit are not yet sufficient to fund the company’s operating structure. Until Immuron reaches breakeven, it remains exposed to continued capital requirements and limited ability to reinvest internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercialization traction
Revenue expansion from $0.15M to $7.55M demonstrates that Immuron has moved beyond an early development profile toward commercial traction. A larger revenue base can support broader distribution, strengthen product awareness, and provide a platform for scaling its gastrointestinal portfolio.
Read all positive factors
Immuron (IMRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.29M
Dividend YieldN/A
Average Volume (3M)4.12M
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth10.41%
EPS Growth40.27%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding8,071,202
10 Day Avg. Volume12,321,955
30 Day Avg. Volume4,120,395
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.04
Price to Sales (P/S)1.51
P/FCF Ratio-3.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$6.43M
Immuron Business Overview & Revenue Model
Company Description
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's acti...
How the Company Makes Money
Immuron makes money primarily through product sales from its commercial gastrointestinal health products and, secondarily, through research and development activities that may generate collaboration-related income when applicable. Its core revenue...
Immuron Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
61
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.55M | 7.29M | 4.90M | 1.80M | 765.19K |
| Gross Profit | 4.87M | 4.77M | 3.34M | 1.74M | 523.50K |
| EBITDA | -4.63M | -5.31M | -5.17M | -3.36M | -3.09M |
| Net Income | -3.75M | -5.22M | -6.94M | -3.79M | -2.85M |
Balance Sheet | |||||
| Total Assets | 12.99M | 10.09M | 15.55M | 21.99M | 24.86M |
| Cash, Cash Equivalents and Short-Term Investments | 9.02M | 5.87M | 11.66M | 18.99M | 22.11M |
| Total Debt | 0.00 | 117.13K | 173.50K | 189.09K | 209.79K |
| Total Liabilities | 1.99M | 2.06M | 2.84M | 2.37M | 1.68M |
| Stockholders Equity | 11.01M | 8.03M | 12.71M | 19.62M | 23.18M |
Cash Flow | |||||
| Free Cash Flow | -3.00M | -6.14M | -5.88M | -2.50M | -3.14M |
| Operating Cash Flow | -3.00M | -6.14M | -5.88M | -2.49M | -3.13M |
| Investing Cash Flow | 2.97M | -2.90M | 327.56K | -2.74M | 11.74K |
| Financing Cash Flow | 6.35M | 199.75K | 829.00 | -35.02K | -36.26K |
Immuron Technical Analysis
Positive
1.16
Price Trends
1.15
Positive
1.09
Positive
1.02
Positive
Market Momentum
0.05
Negative
78.79
Negative
70.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Positive. The current price of 1.16 is below the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.15, and above the 200-day MA of 1.02, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 78.79 is Negative, neither overbought nor oversold. The STOCH value of 70.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMRN.
Immuron Risk Analysis
Immuron disclosed 62 risk factors in its most recent earnings report. Immuron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs could decline significantly and raising capital could be more difficult. Q2, 2024
2.
A material breach in security relating to the Company's information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation. Q2, 2024
Immuron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $9.29M | -3.10 | -31.88% | ― | 10.41% | 40.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $20.20M | -1.31 | -64.75% | ― | -62.70% | -121.27% | |
43 Neutral | $7.25M | -0.54 | -201.06% | ― | ― | ― | |
38 Underperform | $16.90M | -0.63 | -126.02% | ― | ― | 78.51% |
* Healthcare Sector Average
IMRN
Immuron
1.80
-0.08
-4.26%
CANF
Can-Fite BioPharma
2.23
-10.88
-82.99%
LPCN
Lipocine
2.45
-0.46
-15.81%
BIVI
BioVie
2.00
0.20
11.11%
ASBP
Aspire Biopharma Holdings
8.87
-605.17
-98.56%
Immuron Corporate Events
Immuron CEO to Present Company’s Gut Health Pipeline at Emerging Growth Conference
Aug 13, 2026
On August 13, 2026, Immuron Limited announced that chief executive Steven Lydeamore will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, in the U.S. afternoon session. The appearance underscores ongoing efforts...
Immuron CEO to Present TechKnow Invest Roadshow in Melbourne
Jul 21, 2026
Immuron Limited, an Australian biopharmaceutical company, specializes in orally delivered targeted polyclonal antibodies for infectious diseases, led by its Travelan tablet for prevention of travelers’ diarrhea and supported by pipeline cand...
Immuron Showcases Oral Antibody Platform in July 20 Investor Presentation
Jul 20, 2026
Immuron Limited has highlighted its expanding portfolio of orally delivered antibody-based and digestive health therapies, anchored by Travelan for travelers’ diarrhea, IMM‑529 for recurrent C. difficile infection, and ProIBS for irrit...
Immuron Completes Buy-Back of Unmarketable Parcels to Streamline Share Register
Jun 23, 2026
On June 23, 2026, Immuron Limited reported that it has completed a small holding share sale facility for shareholders holding less than a $500 marketable parcel as defined under ASX listing rules, based on a record date of April 8, 2026. Eligible ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.